Asylia Therapeutics ("Asylia"), a development-stage biotechnology company advancing novel immune-modulating therapies for cancer and autoimmune diseases, today announced the closing of a $14.5 million Series A financing led by Sporos Bioventures, LLC. The funds will be deployed to bring Asylia's multiple assets to first-in-human clinical trials for oncology and at the same time potentially generate proof-of-concept signals in auto-immune diseases such as lupus.

Asylia Therapeutics is a private, development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, which collectively impact tens of millions of Americans annually. Founded in 2019 by three physician-scientists at The University of Texas MD Anderson Cancer Center (Robert Orlowski, MD, Ph.D., professor and past chair of the Department of Lymphoma and Myeloma, Ronald A. DePinho, MD, professor and past president, and Richard J. Jones, Ph.D., assistant professor in the Department of Lymphoma and Myeloma), Asylia is based in Houston, Texas. The company's platform centers on a drug pipeline capable of modulating antigen presentation to the immune system which has, to date, produced anti-tumor responses across multiple cancer models. Asylia is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. To learn more, visit www.asyliatx.com